Chirality in ocular agents

Current Opinion in Allergy and Clinical Immunology

Volumn 7, Issue 5, 2007, Pages 418-423

  Leonov, Andrey ^e   Bielory, Leonard ^a,b,c,d  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b Department of Medicine Pediatrics and Ophthalmology

^c Clinical Research and Development   (United States)

^d DOC   (United States)

^e NONE

Author keywords

Chirality; Dextro; Enantiomer; Levo; Ocular medications

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ACETYLCHOLINE; ADRENALIN; AGENTS ACTING ON THE EYE; ANTIALLERGIC AGENT; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARNOSINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CROMOGLYCATE DISODIUM; CYCLODEXTRIN; CYCLOSPORIN A; DEXMEDETOMIDINE; DOPAMINE RECEPTOR STIMULATING AGENT; EPHEDRINE; EPINASTINE; FLURBIPROFEN; IBUPROFEN; KETOROLAC; LEVOCABASTINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORADRENALIN; PHENYLEPHRINE; PYRANENAMINE; SEZOLAMIDE; SK F 84210; TIMOLOL; UNCLASSIFIED DRUG;

ALLERGIC CONJUNCTIVITIS; ANTICHOLINERGIC EFFECT; ANTIOXIDANT ACTIVITY; CATARACT; CENTRAL NERVOUS SYSTEM DEPRESSION; CHIRALITY; DRUG ACTIVITY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG CONFORMATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRY EYE; ENANTIOMER; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STEREOCHEMISTRY; STEREOISOMERISM; UNSPECIFIED SIDE EFFECT;

ANESTHETICS; ANIMALS; ANTI-ALLERGIC AGENTS; CHOLINERGIC ANTAGONISTS; EYE DISEASES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHARMACEUTICAL PREPARATIONS; STEREOISOMERISM; VASOCONSTRICTOR AGENTS;

EID: 34548701338     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3282ef705b     Document Type: Review

References (43)

1. Handley DA, Anderson AJ, Koester J, Snider ME. New millennium bronchodilators for asthma: single-isomer beta agonists. Curr Opin Pulm Med 2000; 6:43-49; Erratum 170.
2. Patil PA, Kothekar MA. Development of safer molecules through chirality. Ind J Med Sci 2006; 60:427-437. Provides an overview of chirality in pharmacology and gives some examples of stereoactive agents.
3. FDA. FDA's policy statement for the development of new stereoisomeric drugs; 1992. http://www.fda.gov/cder/guidance/stereo.htm. [Accessed June 2007]
4. Mitchell JB, Smith J. D-amino acid residues in peptides and proteins. Proteins 2003; 50:563-571.
5. Sela M, Zisman E. Different roles of D-amino acids in immune phenomena. FASEB J 1997; 11:449-456.
6. Armstrong DW, Han SM, Han YI. Separation of optical isomers of scopolamine, cocaine, homatropine, and atropine. Anal Biochem 1987; 167:261-264.
7. Armstrong DW, Ward TJ, Armstrong RD, Beesley TE. Separation of drug stereoisomers by the formation of beta-cyclodextrin inclusion complexes. Science 1986; 232:1132-1135.
8. Mikus P, Valaskova I, Havranek E. Chiral separation of dioxopromethazine in eye drops by CZE with charged cyclodextrin. J Pharm Biomed Anal 2003; 33:157-164.
9. Ghelardini C, Gualtieri F, Novella Romanelli M, et al. Stereoselective increase in cholinergic transmission by R-(+)-hyoscyamine. Neuropharmacology 1997; 36:281-294.
10. Kaila T, Korte JM, Saari KM. Systemic bioavailability of ocularly applied 1% atropine eyedrops. Acta Ophthalmol Scand 1999; 77:193-196.
11. Kentala E, Kaila T, Iisalo E, Kanto J. Intramuscular atropine in healthy volunteers: a pharmacokinetic and pharmacodynamic study. Int J Clin Pharmacol Ther Toxicol 1990; 28:399-404.
12. Stokbroekx RA, Luyckx MGM, Willems JJM, et al. Levocabastine (R 50547): prototype of a chemical series of compounds with specific H1 antihistaminic activity. Drug Dev Res 1986; 8 (May-Aug):87-93.
13. Gluchowski C, Bischoff TE, Garst ME, et al. Synthesis of chiral and achiral pyranenamine derivatives: potent agents with topical ocular antiallergic activity. J Med Chem 1991; 34:392-397.
14. Tasaka K, Kamei C, Izushi K, et al. Comparison of pharmacological properties of optical isomers and a racemic mixture of epinastine. Arzneimittelforschung 1991; 41:219-223.
15. Spampinato S, Marino A, Bucolo C, et al. Effects of sodium naproxen eye drops on rabbit ocular inflammation induced by sodium arachidonate. J Ocul Pharmacol 1991; 7:125-133.
16. van Sorge AA, Wijnen PH, van Delft JL, et al. Flurbiprofen, S(+), eyedrops: formulation, enantiomeric assay, shelf-life and pharmacology. Pharm World Sci 1999; 21:91-95.
17. Tilden ME, Boney RS, Goldenberg MM, Rosenbaum JT. The effects of topical S(+)-ibuprofen on interleukin-1 induced ocular inflammation in a rabbit model. J Ocul Pharmacol 1990; 6:131-135.
18. Handley DA, Cervoni P, McCray JE, McCullough JR. Preclinical enantioselective pharmacology of (R)- and (S)-ketorolac. J Clin Pharmacol 1998; 38 (2 Suppl):25S-35S.
19. Song ZH, Slowey CA. Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2. J Pharmacol Exp Ther 2000; 292:136-139.
20. Savinainen JR, Kokkola T, Salo OM, et al. Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor. Br J Pharmacol 2005; 145:636-645.
21. Agurell S, Halldin M, Lindgren JE, et al. Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 1986; 38:21-43.
22. Vartiainen J, MacDonald E, Urtti A, et al. Dexmedetomidine-induced ocular hypotension in rabbits with normal or elevated intraocular pressures. Invest Ophthalmol Vis Sci 1992; 33:2019-2023.
23. Baldwin JJ, Ponticello GS, Anderson PS, et al. Thienothiopyran-2-sulfonamides: novel topically active carbonic anhydrase inhibitors for the treatment of glaucoma. J Med Chem 1989; 32:2510-2513.
24. Matuszewski BK, Constanzer ML. Indirect chiral separation and analyses in human biological fluids of the stereoisomers of a thienothiopyran-2-sulfonamide (TRUSOPT), a novel carbonic anhydrase inhibitor with two chiral centers in the molecule. Chirality 1992; 4:515-519.
25. Bron A, Lippa EA, Gunning F, et al. Multiple-dose efficacy comparison of the two topical carbonic anhydrase inhibitors sezolamide and MK-927. Arch Ophthalmol 1991; 109:50-53.
26. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 1996; 14:33-38.
27. Share NN, Lotti VJ, Gautheron P, et al. R-enantiomer of timolol: a potential selective ocular antihypertensive agent. Graefes Arch Clin Exp Ophthalmol 1984; 221:234-238.
28. Karhuvaara S, Kaila T, Huupponen R. Beta-adrenoceptor antagonist activities and binding affinities of timolol enantiomers in rat atria. J Pharm Pharmacol 1989; 41:649-650.
29. Richards R, Tattersfield AE. Bronchial beta-adrenoceptor blockade following eyedrops of timolol and its isomer L-714,465 in normal subjects. Br J Clin Pharmacol 1985; 20:459-462.
30. Richards R, Tattersfield AE. Comparison of the airway response to eye drops of timolol and its isomer L-714,465 in asthmatic subjects. Br J Clin Pharmacol 1987; 24:485-491.
31. Crosson CE, Burke JA, Chan MF, Potter DE. Ocular effects of a N,N-disubstituted 5-OH aminotetralin (N-0437): evidence for a dual mechanism of action. Curr Eye Res 1987; 6:1319-1326.
32. Hariton C. Biphasic dose-dependent effects of dopamine and involvement of dopamine autoreceptors on intra-ocular pressure in the rabbit. J Auton Pharmacol 1992; 12:335-347.
33. Hariton C. Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol 1994; 258 (1-2):85-94.
34. Gherezghiher T, Koss MC. Ocular effects of adrenergic stereoisomers in the rabbit. J Ocul Pharmacol 1985; 1:19-28.
35. Rowland JM, Potter DE. Steric structure activity relationships of various adrenergic agonists: ocular and systemic effects. Curr Eye Res 1981; 1:25-35.
36. van Pinxteren PC. Hypotensive effects after topical and intra-arterial administration of alpha-adrenergic agonists in isolated perfused rabbit eyes. Ophthalmic Res 1985; 17:349-353.
37. Babizhayev MA, Deyev AI, Yermakova VN, et al. Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes. Drugs R D 2004; 5:125-139.
38. Holliday R, McFarland GA. A role for carnosine in cellular maintenance. Biochemistry (Mosc) 2000; 65:843-848.
39. Holliday R, McFarland GA. Inhibition of the growth of transformed and neoplastic cells by the dipeptide carnosine. Br J Cancer 1996; 73:966-971.
40. Salazar-Bookaman MM, Wainer I, Patil PN. Relevance of drug-melanin interactions to ocular pharmacology and toxicology. J Ocul Pharmacol 1994; 10:217-239.
41. Eisenberg MS, Maher TJ. Enantiomers of phenylpropanolamine suppress food intake in hyperphagic rats. Pharmacol Biochem Behav 1990; 35:865-869.
42. Potter B, Palmer RA, Withnall R, et al. Two new cyclosporin folds observed in the structures of the immunosuppressant cyclosporin G and the formyl peptide receptor antagonist cyclosporin Hat ultra-high resolution. Org Biomol Chem 2003; 1:1466-1474.
43. de Paulis A, Ciccarelli A, de Crescenzo G, et al. Cyclosporin H is a potent and selective competitive antagonist of human basophil activation by N-formylmethionyl-leucyl-phenylalanine. J Allergy Clin Immunol 1996; 98:152-164.